Market Research Blog

Osteoporosis and osteoarthritis are among the common disabling joint disorders that are affecting millions of elderly people across the world. Some of the most common sites of osteoporotic fractures are the spine, wrists, hips, and shoulders.

Thus, the increasing population suffering from orthopaedic disease is creating high demand for bone growth stimulators. The cause of delayed bone healing and fractures is not known, however, it is creating a large economic impact on the market of bone growth stimulators.

To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/REP-GB-828

Various alternative therapies and treatments for fractures, which include synthetic bone grafts, amputation, and allografts, as well as non-invasive therapies, such as electrical bone growth stimulation and low-intensity ultrasound stimulations, have been introduced, which are responsible for driving the global bone growth stimulators market. According to the latest research by FMI, the global bone growth stimulators market is expected to account for US$ 1,387.7 Mn by the end of 2029. The bone growth stimulators market is estimated to grow at a CAGR of 5.2% through the forecast period 2022-2028. However, factors such as the high prices of devices and product recalls are expected to hamper the growth of the bone growth stimulators market.

Over the past decades, spending on healthcare has grown globally. The growth of the emerging markets and increasing geriatric population in developed economies are among factors expected to boost healthcare spending, which is expected to subsequently expand the bone growth stimulators market. Increasing healthcare spending is expected to boost the demand for bone growth stimulators, which is, in turn, predicted to create high growth opportunities for players in the bone growth stimulators market over the forecast period.

Furthermore, the increasing number of fractures and technological advancements have increased non-invasive, and rapid technologies in the healthcare industry, which is boosting the bone growth stimulators market. Moreover, manufacturers are undertaking various efforts to provide bone growth stimulators that are more versatile and more convenient for patient use. According to the World Bank, around 1.25 million people get injured in road accidents, which leads to fractures and the requirement of fusion surgeries for their treatment every year. These are some of the prime factors that are expected to drive the global Bone growth stimulators market over the forecast period 2019-2029.

The North America bone growth stimulators market and Europe bone growth stimulators market combined are expected to hold a share of approximately 65% of the global bone growth stimulators market during the forecast period. This can be mainly attributed to the high adoption of advanced technology and reduced hospital visits.

Based on the product type, the global bone growth stimulators market has been segmented broadly into non-invasive bone growth stimulators and invasive bone growth stimulators. Non-invasive bone growth stimulators are also segmented into various other sub-segments such as Capacitive Coupling (CC) devices, Pulsed Electromagnetic Field (PEMF) devices, Combined Magnetic Field (CMF) devices, and ultrasound bone growth stimulators. The non-invasive bone growth stimulators segment is expected to hold a prominent share of the global bone growth stimulators market.

Based on applications, the bone growth stimulators market has been segmented into trauma injury & fractures, spinal fusion surgeries, and osteogenesis. In terms of revenue, the trauma injury and fractures segment dominated the global bone growth stimulators market in 2018. Based on the end user, the bone growth stimulators market is segmented into hospitals, homecare settings, orthopaedic clinics, and ambulatory surgical centres. The hospitals segment held the maximum share of the bone growth stimulators market in 2018, and is predicted to continue to dominate the market throughout the forecast period.

Some of the key players operating in the bone growth stimulators market are Zimmer Biomet Holdings Inc., Bioventus LLC, DJO Global, Orthofix Holdings, Inc., Ossatec Benelux Ltd., IGEA, and Ito Co., Ltd.

For critical insights, request for PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-828

Why Future Market Insights?

• Comprehensive analysis on evolving purchase pattern across different geographies
• Detailed insights of market segments and sub-segments for historical as well as forecast period
• A competitive analysis of prominent players and emerging players in the keyword market
• Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

About FMI:

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:

Mr. Debashish Roy
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

Future Market Insights (FMI), in its recent in-depth analysis of the Esophagoscopes and Gastroscopes Market, underscores rising cases of gastrointestinal diseases and growing demand for minimally invasive surgeries as key push factors driving the adoption of esophagoscopes and gastroscopes. The research by FMI covers the current market size of the esophagoscopes and gastroscopes along with forecast analysis for the assessment period of 2022-2028.

The annual growth rate by 2028—rising for a modest 4.6 percent in 2022, is anticipated to stand at 5.3 percent. Analysis of the esophagoscopes and gastroscopes market also reveals an incremental opportunity of US$ 624.8 Mn between 2022 and 2028—surpassing US$ 1.5 Billion in 2028.  Furthermore, key advancements in healthcare technology driving superior innovations in medical devices with enhanced functionalities, will also contribute maximum revenues in the global esophagoscopes and gastroscopes market.

To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/REP-GB-3120

The global esophagoscopes and gastroscopes market showcases a highly consolidated landscape, around 76 percent of which belongs to the top two companies- Olympus Corporation and PENTAX Medical Company.

“Tier 1 manufacturers of the global esophagoscopes and gastroscopes market, comprising Olympus Corporation and PENTAX Medical Company hold a lion’s share, whereas the remaining players contributed approximately 23.6% revenue share to the global market. While mergers and acquisitions and strategic collaborations are the expected key forward market strategies, technology transfer agreements will play a vital role in the overall growth of esophagoscopes and gastroscopes market”, explains the Practice Head, Healthcare & Medical Devices, Future Market Insights

Further competition analysis reveals that top-of-the-line product launches and more emphasis on the strengthening their presence in emerging economies of APAC, will be the key differentiating strategies. “Key players need to efficiently meet requirements of various end users including hospitals, ambulatory surgical centers, specialty clinics, and diagnostic centers, while ensuring customized services, with ease-of-use functionality and state-of-the-art technologies”.

Opportunities in Focus

• Key participants in the global esophagoscopes and gastroscopes market are expected to benefit by exhibiting innovative product design that would further avoid cross contamination and enhance patient safety—specifically in developed economies.
• Under-served patients in APAC’s developing economies, offer a substantial opportunity for medical devices manufacturers—who can leverage the expanding healthcare infrastructure. Moreover, medical expenditure by respective governments would enable installations sophisticated medical devices (endoscopes) in medical institutions, further increasing the demand for esophagoscopes and gastroscopes, in developing nations.

Considerable shift toward minimally invasive endoscopic procedures, is expected to have a significant impact on the overall growth of esophagoscopes and gastroscopes market. Key advantages including reduced blood loss, lower chances of infection, faster recovery, and fewer surgery marks have driven a lot of patients’ focus toward minimally invasive surgeries. Furthermore, faster recovery time and reduced risk of arterial fibrillation are some other critical factors supplementing to the adoption of minimally invasive procedures. The demand for minimally invasive procedures is thus likely to exhibit potential business opportunities for manufacturers of esophagoscopes and gastroscopes.

Ease in getting FDA clearances is a critical factor driving the sales of esophagoscopes and gastroscopes. Contained under the Modernization Act, exemption of devices that were subjected to certain restrictions has worked in the favor of device manufacturers who no longer need to submit premarket submissions and enable FDA to redirect resources. Such exemptions have significantly minimized the time taken for regulatory approval—thereby, reducing the cost of the devices and driving sales growth of esophagoscopes and gastroscopes.

For critical insights, request for PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-3120

Why Future Market Insights?

• Comprehensive analysis on evolving purchase pattern across different geographies
• Detailed insights of market segments and sub-segments for historical as well as forecast period
• A competitive analysis of prominent players and emerging players in the keyword market
• Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

About FMI:

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:

Mr. Debashish Roy
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

A market study presented by FMI ‘ Mucopolysaccharidosis Treatment Market: Global Industry Analysis 2014-2021 and Opportunity Assessment 2022-2029,’ explains the significant factors influencing the current market structure.

According to research, the mucopolysaccharidosis treatment is still emerging, and different geographies have implemented standard treatment options for the condition. However, there is no universally accepted treatment pattern for mucopolysaccharidosis. Mucopolysaccharidosis falls under rare diseases, which is a complex, diverse, constantly evolving field, and there is a significant shortage of medical and scientific data related to it. Mucopolysaccharidosis treatment and diagnosis involves complex managing requirements, which include long-term care, rehabilitation support, and a continuous treatment plan.

Research Activities Uplift Stem Cell Therapy Application in MPS Treatment

In the present scenario, the drugs that are considered for mucopolysaccharidosis treatment, such as aldurazyme, naglazyme, vimizim, elaprase, mepsevii and hunterase, are the only regulated and recommended drugs present in the market. These drugs fall under enzyme replacement therapies, however, with present research initiatives for stem cell therapies, the latter is considered a prominent mucopolysaccharidosis treatment. Clinical research shows that stem cell transplantation covers a large area that is not covered with the more frequently recommended practice of enzyme replacement therapies, which changes the current market structure for mucopolysaccharidosis treatment, prioritising the latter.

Stem cell therapy is a therapeutic option for mucopolysaccharidosis patients suffering from a severe phenotype, as research shows the method can preserve neurocognition or can even help break the progressive neurodegeneration. The method is provided with strict selection criteria, which is followed by maintained regulations. Research shows that stem cell therapy as a treatment option is gaining popularity among healthcare professionals for mucopolysaccharidosis treatment, which can be attributed to the relation of its better reach towards a normal health condition for the patient.

To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/REP-GB-5880

Enzyme Replacement Therapy Remains Lucrative for Market Investors

As per further assessments of the mucopolysaccharidosis treatment market, it has been difficult to collect epidemiological data pertaining to rare diseases, especially mucopolysaccharidosis treatment, which is likely to impede the actual estimation of the economic burden associated with the condition. The cost estimation for each mucopolysaccharidosis treatment type is affecting and, in turn, creating a more vulnerable situation for the businesses and disrupting research & development activities for each company.

Enzyme replacement therapy is the most attractive segment for investors, however, the unavailability of reimbursement plans and precise treatment plans is encouraging most patient in developing regions to opt for symptomatic treatments instead of enzyme replacement therapy, which is still considered to be the standard mucopolysaccharidosis treatment.

Key Players Focus on Clinical Research of Treatment Models

The report segments the mucopolysaccharidosis treatment market into seven regions to elaborate on the regional trends pertaining to the treatment plan. Major players are focusing on increasing their market share in the Asia Pacific market through strategic collaborations with regional research institutes. There is a lack of awareness about rare diseases among the general public as well as in medical healthcare facilities in several emerging economies. According to a survey and industry report, it takes patients in the US an average of 7.6 years and patients in the UK an average of 5.6 years to actually receive a proper diagnosis. Moreover, it involves a team of healthcare professionals to actually get the right mucopolysaccharidosis treatment and diagnosis pattern for reported cases.

Manufacturers are in the process of introducing a considerable number of mucopolysaccharidosis treatment options, which are currently under clinical trials. An estimated 160 and above clinical trials are being performed for mucopolysaccharidosis treatment. Thus, ensuring that the manufacturers take this mucopolysaccharidosis treatment market to be lucrative and potential rich in terms of revenue. Medical research institutes play an important role in this particular market. They are expected to be the bridge between treatment plans and economical solutions for manufacturers, thus leaving an explicable and lucrative model for mucopolysaccharidosis treatment.

The mucopolysaccharidosis treatment market includes companies such as BioMarin Takeda Pharmaceutical Company Limited, Sanofi S.A., and Ultragenyx Pharmaceutical Inc. BioMarin accounts for a significant value share in the present mucopolysaccharidosis treatment market. The currently existing promising drug types are expected to face competition from emerging candidates. In addition the mucopolysaccharidosis treatment products of other companies, such as Sangamo Therapeutics, Inc., REGENXBIO Inc., Sarepta Therapeutics, Abeona Therapeutics, Inc., and others, are also in the pipeline.

For critical insights, request for PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-5880

Why Future Market Insights?

• Comprehensive analysis on evolving purchase pattern across different geographies
• Detailed insights of market segments and sub-segments for historical as well as forecast period
• A competitive analysis of prominent players and emerging players in the keyword market
• Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

About FMI:

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:

Mr. Debashish Roy
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

The global demand for neurovascular guidewires will reach the valuation of nearly US$ 280 million in 2022, witnessing an estimated increase of 3.6% over 2022. Over 2022-2028, the global neurovascular guidewires market revenue is likely to expand 1.5X.

According to a new research study of Future Market Insights,

• Straight tip guidewires, with a current share of more than a third of the total market value, will retain the dominant position in neurovascular guidewires market through 2028.
• Aneurysms and intra-and extra-cranial angioplasty reflect highest applicability of neurovascular guidewires.
• Hospitals, though anticipated to reflect limited investment opportunities in the neurovascular guidewire market, will remain the leading end-use segment with the maximum share in terms of revenue generation.

To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/REP-GB-3121

The Increasing Number of Neurovascular Disease Treatment Alternatives

Neurovascular guidewires, among the latest innovations in the neurovascular disease treatment landscape, has been pushing the number of neurovascular surgeries since introduction. This according to the report will remain a key factor sustaining demand for neurovascular guidewires in the global market over the coming years.

As the advent of technology used in neurovascular surgeries has significantly increased the number of treatment options for neurovascular diseases, the treatment by using neurovascular guidewires is gaining ground rapidly owing to the relatively lower risk associated with surgical treatment, over conventional surgeries. The usage of guidewires is the mainstay for neurovascular therapy, along with new technologies such as coating-based guidewires, which has contributed substantially to the treatment options for complex lesions that are treated surgically.

The increasing number of neurovascular neuroradiology procedures is also boosting the demand for access products, which is another factor driving the neurovascular guidewires market. The number of neurovascular interventions is increasing with growing awareness among surgeons about the cost benefit associated with the neurovascular guidewires. Besides, reimbursement policies for outpatient surgeries are also expected to propel the neurovascular guidewires market revenue. Furthermore, an increase in the number of end users such as ambulatory surgical centers in underdeveloped and developing countries is boosting the number of outpatients cases, which is also expected to drive the overall market for neurovascular guidewires.

Favorable Reimbursement Scenario & Government Support

The growing prevalence and incidence of cerebral infarction, aneurysm, and stroke is projected to fuel the demand for neurovascular guidewires. Growth in the number of patients suffering from ischemic stroke across the world is also estimated to boost the adoption of neurovascular guidewire and contribute to the growth of the global neurovascular guidewire market during the forecast period.

Similarly, increasing incidence of arteriovenous malformations is also contributing to growth in the demand for neurovascular guidewires. The increasing prevalence of intracranial and extracranial angioplasty is another factor that is expected to drive the neurovascular guidewires market.

Neurovascular guidewires are effective and safe devices in neurovascular intervention procedures for patients suffering from neurovascular diseases. Modifications in reimbursement policies are encouraging the number of outpatients in developed countries. Government initiatives and local reimbursement policies pertaining to the usage of neurovascular guidewires are also expected to boost the neurovascular guidewire market over the forecast period.

Rising awareness about cerebral infarction is also estimated to contribute to the growth of the market. The reimbursement policies for the treatment of brain aneurysm are also contributing to the growth of the neurovascular guidewires market as the patients are not required to pay from their own pocket.

FMI’s report tracks some of the key companies operating in the neurovascular guidewire market, which include Boston Scientific Corporation, Medtronic, Penumbra Inc., Stryker, Asahi Intecc Co. Ltd, Integer Holding Corporation, Cordis Corporation, CONMED Corporation, phenox GmbH, and Integer Holding Corporation, among others.

For critical insights, request for PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-3121

Why Future Market Insights?

• Comprehensive analysis on evolving purchase pattern across different geographies
• Detailed insights of market segments and sub-segments for historical as well as forecast period
• A competitive analysis of prominent players and emerging players in the keyword market
• Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

About FMI:

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:

Mr. Debashish Roy
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

According to latest research by FMI, the global disposable spinal instruments market is estimated to have accounted for US$ 43.7 Mn in terms of value in 2021. The report on the disposable spinal instruments market further projects that the disposable spinal instruments market is likely to grow at a CAGR of 8.2% during the period 2022-2029.

Healthcare-Associated Infections or Hospital-Acquired Infections (HAIs) are caused while receiving medical treatment in a hospital facility. HAIs are among the major challenges to the safety of patients, and can have severe public health implications. These infections are also capable of causing disability and sometimes death. The occurrence of HAIs is increasing at an alarming rate. According to WHO, the prevalence of these infections in developed countries varies from 3.5% to 12%. Developing countries are at a higher risk as the rate of infection is 3-20 times higher in developing countries as compared to high-income countries.

In the U.S., more than 15 Mn surgeries are performed annually. Between 2% and 5% of patients are estimated develop a surgical site infection, which is between 160,000 and 300,000 surgical site infections nationwide each year. Surgical site infections are among the most commonly occurring HAIs in the U.S., and are the most expensive to treat. Fortunately, the adoption of various disposable devices and kits has reduced the incidence of surgical site infections and HAIs.

Thus, the increasing preference for the usage of disposable instruments for reducing the occurrence of HAIs is driving the demand for disposable instruments, which is creating growth opportunities for the disposable spinal instruments market.

To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/REP-GB-6890

The demand for disposable instruments kits in the healthcare industry is growing at a significant rate, and the demand from unconventional end-use industries is one of the major factors fuelling the market for disposable spinal instruments. Growth in the number of end users, apart from hospitals, such as orthopaedic clinics and Ambulatory Surgical Centres (ASCs), is expected to create high demand for disposable spinal instruments. Moreover, the adoption of disposable instrument kits by various end users has reduced the risk of infections and cross-contamination, which has resulted in a reduction in the number of HAIs.

Increase in the number of use cases of disposable spinal instruments in hospitals and ASCs is expected to boost the global demand for disposable instrument kits. According to CDC, the number of Medicare-certified ASCs has increased steadily from 239 in 1983 to 5,316 in 2010.

Moreover, increasing geriatric population, which is prone to various types of spinal injuries, is estimated to boost the need for surgeries. This is expected to contribute to the demand for disposable spinal instruments. The increasing requirement of instrument kits during surgeries among the greying population, coupled with improved life expectancy, has created significant growth opportunities for the manufactures of disposable spinal instruments market. However, factors such as stringent regulations and the generation of a significant amount of waste due to the usage of disposable kits is expected to lower the growth of disposable spinal instruments in the forecast period.

The disposable spinal instruments kits segment is a leading segment in terms of revenue by product type in the disposable spinal instruments market, with a 64.5% revenue share in 2021. These kits are most widely used in cervical and lumbar surgeries such as spinal fusion and decompression surgeries. Among the procedure type segments, the spinal fusion sub-segment accounts for the largest revenue share in the disposable spinal instruments market. Among all the end users in the disposable spinal instruments market, the hospitals sub-segment is expected to be a prominent segment, followed by the orthopaedic clinics sub-segment.

The disposable spinal instruments market has been analysed across the regions of North America, Latin America, Europe, East Asia, South Asia, Oceania, and MEA. North America, followed by Europe, is a prominent region in the global disposable spinal instruments market. North America accounted for a revenue share of 45.8% in 2021 in disposable spinal instruments market. Europe, accounting for the second-largest revenue share, is followed by East Asia in the disposable spinal instruments market. India, China, and Brazil are emerging markets in the disposable spinal instruments market. China is one of the fastest-growing emerging markets in the global disposable spinal instruments market, and is projected to grow at a CAGR of 11.2% over the forecast period of 2022-2029.

The disposable spinal instruments market report tracks some of the key companies operating in the disposable spinal instruments market, such as ECA Medical, Providence Medical Technology, Inc., Xenco Medical, Paradigm Spine, Intelligent Implant Systems, LLC, Safe Orthopaedics, SA , TeDan Surgical Innovations, LLC, and Joimax GmbH. Majority of the regional players in the disposable spinal instruments market are focused on increasing their product reach and connectivity with the regional distributors of disposable spinal instruments. The manufacturers of disposable spinal instruments are focusing on collaborating with established hospitals and ASCs to sell products as some of the medical practitioners are particular about the type and brand of products used for a surgical procedure.

For critical insights, request for PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-6890

Why Future Market Insights?

• Comprehensive analysis on evolving purchase pattern across different geographies
• Detailed insights of market segments and sub-segments for historical as well as forecast period
• A competitive analysis of prominent players and emerging players in the keyword market
• Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

About FMI:

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:

Mr. Debashish Roy
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

Remarkable increase in the companion animal ownership and strong growth of development of the veterinary healthcare infrastructure collectively push the sales of companion animal vaccines in global market. Surpassing the revenues worth US$ 2.5 Bn in 2021, global companion animal vaccines market is projected to exhibit a robust CAGR during 2022 – 2029. Measurable rise in the zoonotic disease prevalence will remain a key factor fueling the demand for companion animal vaccines and drugs.

FDA approvals for novel and innovative companion animal vaccines continue to present potential growth opportunities to R&D of companion animal vaccines. For instance, Zoetis received regulatory approval for ProHeart, used for prevention of heartworm diseases caused by Dirofilaria immitis in dogs.

Key Takeaways – Companion Animal Vaccines Market Study

• Attenuated live vaccines currently account for more than a third of total market value, and will continue to witness a healthy CAGR through 2029. This demand growth is attributed to their improved effectivity and enhanced long-term preventive action.
• North America is witnessing lucrative market growth compared to other regions attributed to increase in the adoption rate of companion animals, increase in veterinary healthcare expenditure, and increasing awareness about pet health.
• Veterinary animal hospitals and clinics offering better service support for animal care are expected to  have  significant market share during the forecast period
• As large number of people are in close contact with canine animals as a preference for companion animal, demand will be prominent among canine species.

To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/REP-GB-1427

Increasing R&D Investments to Widen Market Growth Prospects

Elanco, Ceva Sante Animale, Boehringer Ingelheim are among the leading market players in the companion animal vaccines market. These manufacturers continue to dominate the market landscape of companion animal vaccines by investing heavily in R&D activities to develop and launch therapeutic vaccines for prevention and treatment of various animal diseases. Surge in investment for R&D of vaccines, which inhibit the growth of antibiotic-resistant organisms boosts the animal vaccines market growth.

For instance, in August 2021, Elanco invested two-thirds of the budget for food‐animal unit to develop vaccines and reduce the use of antibiotics. Moreover, rise in demand for animal vaccines led to the development of multiple new vaccines. For instance, Cevac IBron a new vaccine was launched by Ceva in February 2017 for prevention against infectious bronchitis virus (IBV) in animals.

Know More About Companion Animal Vaccines Market Report

Future Market Insight brings the comprehensive research report on forecast revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2029. The global companion animal vaccines is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights of the companion animal vaccines market on basis of product type (attenuated live vaccines, conjugated vaccines, inactivated vaccines, subunit vaccines, toxoid vaccines, DNA vaccines, recombinant vaccines), species type (canine, avian, feline) and distribution channel (companion animal hospitals, companion animal hospitals, companion animal research institutes) across seven major regions.

For critical insights, request for PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-1427

Why Future Market Insights?

• Comprehensive analysis on evolving purchase pattern across different geographies
• Detailed insights of market segments and sub-segments for historical as well as forecast period
• A competitive analysis of prominent players and emerging players in the keyword market
• Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

About FMI:

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:

Mr. Debashish Roy
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

The global demand for venous thromboembolism treatment market is likely to grow steadily over the forthcoming years. As indicated by a recent Future Market Insights (FMI) study, the market revenues will observe approximately 3.7% CAGR between 2022 and 2029.

More than 3/5^th of treatment demand is underpinned by deep venous thrombosis, according to the report. Catheter-directed thrombolysis devices and percutaneous thrombectomy devices, collectively account for more than half of the global revenues represented by the venous thromboembolism treatment market.

Venous thromboembolism treatment involves segmented pneumatic compression pumps without gradient, segmented pneumatic compression pumps with calibrated gradient, lower pneumatic compression sleeves, non-segmented pneumatic compression pumps permanent inferior vena cava filters, retrievable inferior vena cava filters, embolectomy balloon catheters, percutaneous thrombectomy devices, catheter-directed thrombolysis (CDT) devices and upper pneumatic compression sleeves. Based on the disease indication, deep vein thrombosis is expected to hold a prominent share in the overall venous thromboembolism treatment market.

Poor Reimbursement Scenario Against High Treatment Costs to Restrict Adoption

Several factors are impacting the overall growth of the venous thromboembolism treatment market. The first and the most important factor driving the venous thromboembolism treatment market is the increasing prevalence of venous thromboembolism disease. Other factors, such as the increasing retrieval rate of vena cava filters, increasing healthcare awareness, presence of favourable reimbursement policies, and increasing geriatric population, are also responsible for the growth of the venous thromboembolism treatment market.

To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/REP-GB-1341

Apart from the driving factors of venous thromboembolism treatment market, there are few factors that are likely to hinder the overall growth of the venous thromboembolism treatment market. The high cost associated with venous thromboembolism treatment therapy, poor reimbursement for some of the treatment devices, and poor insurance support are among the major factors that are expected to hamper the growth of the venous thromboembolism treatment market.

Drug-based Treatment Witnessing Traction across Europe

Although increasing preference for drug-based venous thromboembolism treatment is highly likely to hinder the growth of the market, new-generation drugs, including non-Vitamin K antagonist oral anticoagulants (NOACs) such as dabigatran, rivaroxaban, apixaban, and edoxaban, are estimated to boost the adoption rate of venous thromboembolism treatment due to increased efficacy. However, there are regional variations to this trend.

North America is expected to be a prominent region in the global venous thromboembolism treatment market because of the presence of a well-developed healthcare infrastructure and numerous technological advancements in the region. The increasing prevalence of venous thromboembolism is also responsible for the boosting the growth of the North America market. Treatment using mechanical and interventional prophylaxis systems is expected to be increasingly adopted in the North American region during the forecast period. In addition, drug-based treatment is expected to gain popularity in the European region, which is expected to subsequently decrease the usage of mechanical and interventional treatments in the region.

On the other hand, increasing per capita healthcare expenditure is one of the macroeconomic factors that is likely to boost the market. Nowadays, certain changes in the socio-economic scenario can also lead to significant growth in the venous thromboembolism treatment market.

Tier 1 Players Account for Nearly 35% Market Revenue Share

Some of the key manufacturers of venous thromboembolism treatment are mainly focusing on innovating and launching new and advanced products. Major players in the venous thromboembolism treatment market are focusing on collaborations and acquisitions. For example, venous thromboembolism treatment is majorly adopted by hospitals, catheterisation laboratories, and ambulatory surgical centres. Hospitals are expected to hold a significant revenue share in the venous thromboembolism treatment market.

The report tracks some of the key companies operating in the venous thromboembolism treatment market such as ArjoHuntleigh AB, AngioDynamics, Cardinal Health Inc., BTG International Ltd., Stryker Corporation, DJO Global Inc., EKOS Corp, and Teleflex Inc., Boston Scientific Corp.  There are several other companies operating in the venous thromboembolism treatment market. AngioDynamics, Boston Scientific Corp., and Cardinal Health Inc. are expected to hold a prominent share in the venous thromboembolism treatment market. These tier 1 companies hold a share of approximately 35% in the venous thromboembolism treatment market.

For critical insights, request for PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-1341

Why Future Market Insights?

• Comprehensive analysis on evolving purchase pattern across different geographies
• Detailed insights of market segments and sub-segments for historical as well as forecast period
• A competitive analysis of prominent players and emerging players in the keyword market
• Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

About FMI:

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:

Mr. Debashish Roy
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

According to the latest research by the FMI, the global urology imaging systems market is expected to account for over US$ 486.4 Mn, in terms of value, by 2028 end. The report on the Urology Imaging Systems market further projects substantial growth potential with CAGR of 3.7% over 2022-2028.

While hospitals will continue to register the highest revenue share in terms of urology imaging systems adoption, the report highlights limited investment opportunities for manufacturers of urology imaging systems, within clinics.

Increasing EU Reserve Funding Encouraging Adoption of Urology Imaging Systems

Increasing instances of urological disease and simultaneously increasing awareness about critical health issues is anticipated to boost demand for urology imaging systems and services across globe. Accessibility of EU reserves for part states in the CEE, paralleled by administrative projects in Russia, will be an imperative source of financing for new imaging equipment purchases and will contribute fundamentally to the advancement of the urology imaging systems market in the Eastern Europe.

To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/REP-GB-8911

In Russia, the 2020 Healthcare Development Program and National Project ‘Health’ center not just around conveying propelled advances to the nation and furnishing healthcare facilities with costly, top of the line urology imaging systems, yet additionally on obtaining mid-range and low-end urology imaging systems that are very required in local health facilities. The compliance to the EU reserve funding has given access to countries like the Czech Republic, Hungary, Poland, Bulgaria and Romania. Such compliances are anticipated to eliminate barriers for the new entrant in urology imaging systems market.

The growing demand for urology imaging systems is centered at increasing inclination towards technologically-advanced imaging tools used in the diagnosis of prostate cancer and uterine fibroid to reduce the risk of uterine cancer. Further increasing demand for urology imaging systems for accurate diagnosis and second opinion is anticipated to create demand for ultrasound- as well as fluoroscopy-based urology imaging systems, thereby driving the growth of the Urology Imaging Systems market. However, ultrasound systems are likely to continue representing a larger market value share over fluoroscopic variants, according to FMI’s analysis.

Favorable Reimbursement Scenario, Supported by Increasing Number of Diagnostic Establishments Driving Market Growth

In the recent years, the number of independent diagnostics and imaging centers in various developed and developing regions has seen a significant spike, overcoming a series of volume and reimbursement pressures in an effort to sustain profitability and achieve better margins. This according to the report is expected to drive the growth of the Urology Imaging Systems market.

Many insurance companies have adopted effective marketing strategies to shift the patient volume to low-cost independent diagnostic centers and reduce the price point associated with urology imaging systems. Independent diagnostic imaging centers offer better service and often of superior quality, generally at the expense of local hospitals and weak operators. The development of low cost portable urology imaging systems is providing leverage to current imagining centers and subsequently driving the growth of Urology Imaging Systems market.

The report tracks strategic developments of some of the prominent players competing in  the global urology imaging systems market, including GE Healthcare, Toshiba Medical, Philips Healthcare, Hitachi-Aloka Medical, Siemens Healthineers, Samsung Medison, Mindray, Fujifilm Sonosite, Esaote, and Analogic. The report also provides key aspects and trends in the Urology Imaging Systems market, including reimbursement scenario, average selling price, and country-wise revenue analysis.

For critical insights, request for PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-8911

Why Future Market Insights?

• Comprehensive analysis on evolving purchase pattern across different geographies
• Detailed insights of market segments and sub-segments for historical as well as forecast period
• A competitive analysis of prominent players and emerging players in the keyword market
• Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

About FMI:

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:

Mr. Debashish Roy
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com